KR102720889B1 - Method of providing direct transaction ledger service of pharmacies and customers by determining reliability of efficacy of medicines based on big data processing and providing them to users - Google Patents

Abstract

The present invention relates to a method for providing a direct transaction ledger service between a pharmacy and a business partner, which provides users with a judgment on the reliability of the efficacy of a pharmaceutical product based on big data processing.

Description

Method of providing a direct transaction ledger service between pharmacies and customers by determining reliability of efficacy of medicines based on big data processing and providing them to users {METHOD OF PROVIDING DIRECT TRANSACTION LEGGER SERVICE OF PHARMACIES AND CUSTOMERS BY DETERMINING RELIABILITY OF EFFICACY OF MEDICINES BASED ON BIG DATA PROCESSING AND PROVIDING THEM TO USERS}

The present invention relates to a method for providing a direct transaction ledger service between a pharmacy and a business partner, which provides users with a judgment on the reliability of the efficacy of a pharmaceutical product based on big data processing.

Pharmacies provide consumers who wish to purchase medicines with the correct medicine according to symptoms and prescriptions based on their professional knowledge in the pharmaceutical field. To this end, they purchase medicines as products through direct transactions with pharmaceutical manufacturers or through wholesale transactions with wholesalers. They form a B2B distribution structure in their relationship with pharmaceutical manufacturers and wholesalers, and a B2C distribution structure in their relationship with pharmaceutical consumers. They play a central role in the distribution of pharmaceuticals.

Meanwhile, pharmaceutical manufacturers and wholesalers generally have their own electronic transaction ledger systems for distribution and inventory management, and sales representatives who act as intermediaries between pharmaceutical manufacturers and wholesalers and pharmacies record the status of pharmaceutical transactions through terminal devices connected to the electronic transaction ledger systems of the pharmaceutical manufacturers and wholesalers.

However, pharmacies have separate electronic transaction ledger systems that are independent of the electronic transaction ledger systems of pharmaceutical manufacturers and wholesalers, or have analog ledger systems such as manual ledgers to record the status of pharmaceutical transactions and even manage their own inventory.

As the pharmacy's own system or ledger system is configured separately from the electronic transaction ledger system of the pharmaceutical manufacturer and wholesaler, despite the central role that the pharmacy plays in the pharmaceutical distribution process, the pharmacy must record and manage various transactions such as inventory management, purchase, and return of pharmaceuticals using both the electronic transaction ledger system of the pharmaceutical manufacturer and wholesaler and its own ledger system, so the entity operating the pharmacy is faced with a double burden of work in terms of ledger management.

In particular, as the pharmaceutical industry continues to develop, pharmacies are required to handle various types of medicines, but as pharmacies must handle all of the above-mentioned conventional dual ledger systems in the distribution process of medicines, the burden on entities operating pharmacies is increasing day by day.

In addition, since the ledger system that pharmacies must handle is divided into two, there is always a possibility of errors and inconsistencies in the transaction ledgers, which ultimately leads to a decline in the reliability of pharmaceuticals for consumers. In addition, despite the central role that pharmacies play in the pharmaceutical distribution process, if the pharmaceuticals that consumers need are not provided in a timely manner due to inventory management issues caused by difficulties in ledger management, this can have a negative impact on the health of the general public.

Furthermore, transaction managers such as sales representatives of pharmaceutical manufacturers and wholesalers who form B2B distribution relationships with pharmacies typically conduct transactions with more than 150 pharmacies as suppliers. Since the pharmacies' own ledger systems differ from those of the pharmaceutical manufacturers and wholesalers, there is a possibility that ledger inconsistencies may arise during the communication process with the suppliers, and from the perspective of pharmacies as well, they typically conduct transactions with more than 20 to 30 pharmaceutical manufacturers and wholesalers as suppliers. As orders and returns are processed in an analog manner due to this dual ledger system, communication is not smooth, and the immediate and simultaneous communication causes unnecessary waiting times and inconveniences due to responses.

Patent Publication No. 10-2023-0049213, published on April 13, 2023

The present disclosure has been made to solve the above-described problems, and the purpose of the present disclosure is to provide a method for providing a direct transaction ledger service between a pharmacy and a business partner by replacing the dual manual ledger between the pharmacy and the business partner with an electronic ledger, thereby improving the convenience of management and reliability.

In addition, the purpose of the present disclosure is to provide a method and device for more efficiently conducting direct transactions and communication between pharmaceutical dealers such as pharmaceutical manufacturers and wholesalers and pharmacies.

Furthermore, the purpose of the present disclosure is to provide a method and device for more efficiently conducting direct transactions and communication between pharmaceutical dealers such as pharmaceutical manufacturers and wholesalers and pharmacies, thereby increasing mutual trust through transparent bookkeeping from the perspectives of both pharmaceutical dealers and pharmacies, increasing convenience through unifying communication, enhancing efficiency in sales management through recording and storing the history of communication with pharmacies, and improving inventory management and reliability of transactions by establishing an efficient and systematic payment system.

Furthermore, the purpose of the present disclosure is to provide a method and device for more efficiently conducting direct transactions and communication between pharmaceutical dealers, such as pharmaceutical manufacturers and wholesalers, and pharmacies, thereby increasing sales by activating direct transactions from the perspective of pharmaceutical dealers, and achieving high-level sales by easily managing numerous transaction pharmacies through a data-based platform from the perspective of sales personnel, increasing distribution margins, reducing sales costs, and providing specialized information on pharmaceuticals and information on sales strategies.

Furthermore, the purpose of the present disclosure is to provide a method and device for more efficiently conducting direct transactions and communication between pharmaceutical dealers and pharmacies, thereby increasing the convenience of management by activating direct transactions from the perspective of the pharmacy, easily managing numerous pharmaceutical dealers through a data-based platform from the perspective of an entity operating a pharmacy, increasing distribution margins and reducing pharmacy management costs, efficiently performing pharmacy management, providing excellent service to pharmaceutical consumers based on professional information on pharmaceuticals provided by pharmaceutical dealers, information on sales strategies, and professional knowledge of pharmacists, and achieving the improvement of national health by providing necessary pharmaceuticals at the right time.

The problems to be solved by the present disclosure are not limited to the problems mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the description below.

As an example of the present disclosure, a method for providing a pharmaceutical electronic transaction ledger management service performed by a device includes: a step of displaying a main screen including a first user interface (UI) for selecting one or more business partners and a second UI for indicating a user's transaction status; a step of displaying a third UI for purchasing a plurality of pharmaceuticals sold by the first business partner based on the selection of a first business partner from among the one or more business partners through the first UI; a step of displaying a fourth UI for ordering the first pharmaceutical product based on the selection of the first pharmaceutical product from among the plurality of pharmaceutical products through the third UI and a fifth UI including information on a plurality of pharmaceutical products of the same type as the first pharmaceutical product sold by the remaining business partners excluding the first business partner; and a step of updating the second UI based on information related to the purchase of the first quantity of the first pharmaceutical product based on a user command for ordering a first quantity of the first pharmaceutical product being input through the fourth UI, wherein the fourth UI may include efficacy, effect, usage, and dosage of the first pharmaceutical product.

And, the method may further include a step of transmitting the user's order information for the first quantity of the first medicine to a terminal device used by the first business partner; a step of receiving delivery schedule information of the first medicine received from the terminal device used by the first business partner and the delivery company used by the first business partner; and a step of providing delivery schedule information of the first medicine.

And, the method further includes a step of providing comparison information between the first medicine and the second medicine based on the selection of the second medicine from among a plurality of medicines of the same type as the first medicine, and the comparison information between the first medicine and the second medicine may include price comparison information, efficacy comparison information, evaluation score comparison information, and discount information according to order quantity between the first medicine and the second medicine.

And, the main screen includes a search UI that can search for at least one of a business partner, a medicine, and an effect, and based on a second business partner being searched through the search UI, information on a plurality of medicines sold by the second business partner is provided through a search result UI, and based on a third medicine being searched through the search UI, information on the third medicine and information on a plurality of medicines of the same type as the third medicine are provided through the search result UI, and based on a specific effect being searched through the search UI, information on a plurality of medicines targeting the specific effect can be provided through the search result UI.

And, the priority of each of at least one medicine provided in the search result UI is determined based on the evaluation score and price of each of the at least one medicine, and the at least one medicine can be arranged in the search result UI according to the determined priority of each of the at least one medicine.

And, the method may further include a step of providing a first message asking the user whether to request a consultation with the first business partner for an additional purchase of the first pharmaceutical product; a step of transmitting a second message requesting a consultation for an additional purchase of the first pharmaceutical product to a terminal device used by the first business partner based on a request for a consultation with the first business partner in response to the first message; and a step of providing a video meeting UI capable of conducting a video meeting with the terminal device used by the first business partner on the coordinated schedule based on the schedules between the user and the first business partner being coordinated.

In addition, the video meeting UI includes a purchase UI that can purchase a plurality of medicines sold by the first business partner, and the price of a fourth medicine purchased in the purchase UI among the plurality of medicines sold by the first business partner can be determined by agreement between the first business partner and the user.

And, the second UI includes an icon for refunding all or part of the first quantity of the first medicine purchased, and based on the selection of the icon, an inquiry UI for inquiring about the reason for refunding all or part of the first medicine is provided, and the reason for refunding all or part of the first medicine entered in the inquiry UI can be transmitted to a terminal device used by the first business partner.

In addition, a computer-readable recording medium recording a computer program for executing a method for implementing the present disclosure may be further provided.

According to various embodiments of the present disclosure, a method and device for providing a pharmaceutical electronic transaction ledger management service can be provided.

By various embodiments of the present disclosure, the management efficiency of a pharmacy selling medicines and the management efficiency of pharmacies of business partners can be improved.

The effects of the present disclosure are not limited to the effects mentioned above, and other effects not mentioned will be clearly understood by those skilled in the art from the description below.

FIG. 1 is a schematic diagram illustrating a system for implementing a method for providing a pharmaceutical electronic transaction ledger management service according to one embodiment of the present disclosure.
FIG. 2 is a block diagram illustrating the configuration of a device that provides a pharmaceutical electronic transaction ledger management service according to one embodiment of the present disclosure.
FIG. 3 is a flowchart illustrating a method for providing a pharmaceutical electronic transaction ledger management service according to one embodiment of the present disclosure.
FIG. 4 is a flowchart illustrating a method for negotiating a pharmaceutical purchase via a video conference according to one embodiment of the present disclosure.
FIG. 5 is a flowchart illustrating a method for performing payment and return procedures for pharmaceutical products according to one embodiment of the present disclosure.
FIGS. 6a, 6b, 6c, 6d, and 6e illustrate a UI providing a pharmaceutical electronic transaction ledger management service according to one embodiment of the present disclosure.

The advantages and features of the present disclosure, and the methods for achieving them, will become apparent by referring to the embodiments described in detail below together with the accompanying drawings. However, the present disclosure is not limited to the embodiments disclosed below and may be implemented in various different forms, and these embodiments are provided only to make the disclosure of the present disclosure complete and to fully inform a person skilled in the art of the scope of the present disclosure, and the present disclosure is defined only by the scope of the claims.

The terminology used herein is for the purpose of describing embodiments only and is not intended to be limiting of the present disclosure. In this specification, the singular also includes the plural unless specifically stated otherwise. The terms "comprises" and/or "comprising" as used herein do not exclude the presence or addition of one or more other components other than the mentioned components.

Throughout the specification, the same reference numerals refer to the same elements, and "and/or" includes each and every combination of one or more of the elements mentioned. Although "first", "second", etc. are used to describe various elements, it is to be understood that these elements are not limited by these terms. These terms are merely used to distinguish one element from another. Accordingly, it should be understood that a first element mentioned below may also be a second element within the technical scope of the present disclosure.

Unless otherwise defined, all terms (including technical and scientific terms) used in this specification may be used with the meaning commonly understood by those skilled in the art to which this disclosure belongs. In addition, terms defined in commonly used dictionaries shall not be ideally or excessively interpreted unless explicitly specifically defined.

The spatially relative terms "below," "beneath," "lower," "above," "upper," and the like can be used to easily describe the relationship of one component to another, as illustrated in the drawings. The spatially relative terms should be understood to include different orientations of the components when used or operated, in addition to the orientations illustrated in the drawings.

For example, when a component depicted in a drawing is flipped, a component described as "below" or "beneath" another component may be placed "above" the other component. Thus, the exemplary term "below" may include both the above and below directions. Components may also be oriented in other directions, and thus spatially relative terms may be interpreted according to the orientation.

In describing the present disclosure, a "user" may collectively refer to an entity operating a pharmacy registered in an application and/or website operating a pharmaceutical electronic transaction ledger management service. In other words, a "user" may collectively refer to an entity transacting pharmaceuticals with a business partner through an application and/or website operating a pharmaceutical electronic transaction ledger management service.

"Business Partner" may collectively refer to a pharmaceutical company registered in an application and/or website operating a pharmaceutical electronic transaction ledger management service, or an administrator working at such pharmaceutical company. In other words, "Business Partner" collectively refers to an entity that sells pharmaceuticals to users through an application and/or website operating a pharmaceutical electronic transaction ledger management service. Examples of "Business Partners" may include various pharmaceutical companies, health functional food companies, animal medicine companies, pharmacy supplies companies, OEM companies, over-the-counter drug companies, etc., and may also include manufacturers that produce products handled by pharmacies, and distributors such as wholesalers.

"Server" means a server device used by a company that manages an application and/or website that operates a pharmaceutical electronic transaction ledger management service. In other words, operations and data related to the application and/or website can be managed and controlled by the "server."

Below, a method for providing a pharmaceutical electronic transaction ledger management service is specifically described with reference to the drawings.

FIG. 1 is a schematic diagram illustrating a system for implementing a method for providing a pharmaceutical electronic transaction ledger management service according to one embodiment of the present disclosure.

As illustrated in FIG. 1, a system (1000) for implementing a method for providing a pharmaceutical electronic transaction ledger management service may include a device (100) (used by a user), terminal devices (200-1, 200-2, ?? 200-N) used by multiple business partners (N is a natural number greater than or equal to 2), and a server (300).

Here, Fig. 1 illustrates a case where a device (100) used by a user is implemented in the form of a single desktop, and a case where terminal devices (200-1, 200-2, ?? 200-N) used by multiple business partners are implemented in the form of a single smart phone, but is not limited thereto.

Each device may be implemented as a different type of electronic device (e.g., a notebook, a desktop, a laptop, a tablet PC, a slate PC device, a server device, etc.), and may also be implemented as a device family in which one or more types of devices are connected.

In addition, although Fig. 1 illustrates a case where there is only one user, it is not limited thereto. Multiple pharmacies may be registered in an application and/or website that operates a pharmaceutical electronic transaction ledger management service, and the system (1000) may include devices used by each of multiple users who operate multiple pharmacies.

A plurality of users and/or a plurality of business partners may regularly pay a registration fee for registering with an application and/or a website operating a pharmaceutical electronic transaction ledger management service. Additionally or alternatively, each of the plurality of users and/or the plurality of business partners may pay a certain portion of a specific pharmaceutical transaction amount as a fee when transacting a specific pharmaceutical on the application and/or website operating a pharmaceutical electronic transaction ledger management service. The amount paid by the plurality of users and/or the plurality of business partners may be deposited into the account of the company operating the server (300).

Each of the multiple users can deposit a deposit amount into a deposit account corresponding to each of the multiple users on the application and/or website that operates the pharmaceutical electronic transaction ledger management service. Each of the multiple users can purchase pharmaceuticals sold by the transaction partner with the amount deposited into the deposit account.

The device (100) included in the system (1000), terminal devices (200-1, 200-2, ?? 200-N) used by multiple business partners, and server (300) can perform communication via a network (W).

Here, the network (W) may include a wired network and a wireless network. For example, the network may include various networks such as a local area network (LAN), a metropolitan area network (MAN), and a wide area network (WAN).

Additionally, the network (W) may include the well-known World Wide Web (WWW). However, the network (W) according to the embodiment of the present disclosure is not limited to the networks listed above, and may include at least a portion of a well-known wireless data network, a well-known telephone network, or a well-known wired/wireless television network.

The device (100) used by the user can input information about the pharmacy operated by the user into an application and/or website that operates a pharmaceutical electronic transaction ledger management service.

Here, the fact that the device (100) used by the user inputs information about the corresponding pharmacy into the application and/or website operating the electronic transaction ledger management service may mean that the device (100) transmits information about the corresponding pharmacy to the server (300). Accordingly, the pharmacy operated by the user may be registered in the application and/or website operating the electronic transaction ledger management service, and may thereby receive the electronic transaction ledger management service.

In a similar manner, each of the terminal devices (200-1, 200-2, ?? 200-N) used by multiple business partners can transmit information for registration to the server (300) in an application and/or website that operates an electronic transaction ledger management service.

Users who operate pharmacies and business partners who sell medicines can more efficiently conduct medicine transactions, manage sales history, return, and communicate through applications and/or websites that operate electronic transaction ledger management services.

In explaining the present disclosure, the operations performed by the device (100) used by the user and/or the terminal devices (200-1, 200-2, ?? 200-N) used by multiple business partners (via an application and/or a website operating an electronic transaction ledger management service) may include operations performed by the device (100) used by the user and/or the terminal devices (200-1, 200-2, ?? 200-N) used by multiple business partners based on various types of information received from the server (300).

The process by which users and business partners perform various procedures through an application and/or website that operates an electronic transaction ledger management service is explained with reference to FIGS. 2 to 6e.

FIG. 2 is a block diagram briefly illustrating the configuration of a user's device that provides a pharmaceutical electronic transaction ledger management service according to one embodiment of the present disclosure.

As illustrated in FIG. 2, the device (100) may include a memory (110), a communication module (120), a display (130), and a processor (140).

However, the configuration illustrated in FIG. 2 is an example for implementing embodiments of the present disclosure, and appropriate hardware and software configurations that are obvious to those skilled in the art may be additionally included in the device (100).

The memory (110) can store one or more instructions for the processor (140) to perform various operations. The memory (110) can store data supporting various functions of the device (100) and a program for the operation of the processor (140), and can store input/output data (e.g., drug transaction history of a pharmacy operated by a user, types of business partners registered as frequently used by the user among multiple business partners, etc.).

The memory (110) may include at least one type of storage medium among a flash memory type, a hard disk type, an SSD (Solid State Disk type), an SDD (Silicon Disk Drive type), a multimedia card micro type, a card type memory (for example, an SD or XD memory, etc.), a random access memory (RAM), a static random access memory (SRAM), a read-only memory (ROM), an electrically erasable programmable read-only memory (EEPROM), a programmable read-only memory (PROM), a magnetic memory, a magnetic disk, and an optical disk.

The communication module (120) may include one or more components including a circuit that enables communication with an external device (e.g., a server and/or terminal devices used by each of multiple business partners). For example, the communication module (120) may include at least one of a broadcast reception module, a wired communication module, a wireless communication module, a short-range communication module, and a location information module.

The display (130) displays (outputs) information processed in the device (100). For example, the display (130) may display execution screen information of an application program (for example, an application that operates an electronic transaction ledger management service) running in the device (100), or UI (User Interface) (for example, a main screen, payment UI, inquiry UI, video meeting UI, return UI, etc.), GUI (Graphical User Interface) information according to such execution screen information.

The processor (140) can provide a method for providing a pharmaceutical electronic transaction ledger management service by executing one or more instructions stored in the memory (110). That is, the processor (140) can control the overall operation and function by using each component of the device (100).

Specifically, the processor (140) may be implemented as a memory that stores data for an algorithm for controlling the operation of components within the device (100) or a program that reproduces the algorithm, and at least one processor that performs the above-described operation using the data stored in the memory. In this case, the memory and the processor may be implemented as separate chips. Alternatively, the memory and the processor may be implemented as a single chip.

In addition, the processor (140) may control one or more of the components described above in combination to implement various embodiments according to the present disclosure described in FIGS. 3 to 6e below on the device (100).

FIG. 3 is a flowchart illustrating a method for providing a pharmaceutical electronic transaction ledger management service according to one embodiment of the present disclosure.

The device can display a main screen (of an application and/or website operating an electronic transaction ledger management service) including a first UI for selecting one or more business partners and a second UI for displaying the user's transaction status (S310).

As an example of the present disclosure, as illustrated in FIG. 6a, the first UI (610) may include icons representing each of one or more business partners (e.g., icons composed of the logos of the business partners). As an example, icons corresponding to business partners(s) with which the user has conducted business among the one or more business partners may be preferentially arranged on the first UI.

The icon corresponding to a business partner with whom the user has not transacted may include text (e.g., "Transaction Request") indicating whether the user intends to transact for the first time. Accordingly, the user can efficiently distinguish between business partners with whom the user has transacted and business partners with whom the user has not transacted through the first UI.

As an example of the present disclosure, when an icon corresponding to a specific business partner is selected to conduct the first transaction with a specific business partner among one or more business partners, the device may provide an advertisement UI that provides information on the type of medicine and discounts sold by the specific business partner. The type of medicine and discounts sold by the specific business partner included in the advertisement UI may be created and set by the specific business partner.

The second UI (620) may include the amount ordered by the user during a certain period (e.g., the current month), the amount to be paid (i.e., the amount of medicine registered in the shopping cart but not yet paid for), the number of return requests, and the number of non-approved returns.

Additionally, the second UI (620) can display the type, quantity, and amount of medicines ordered by the user (i.e., registered in the shopping cart) by business partner.

Based on the selection of a first customer among one or more customers through the first UI, the device can display a third UI for purchasing multiple medicines sold by the first customer (S320).

As an example of the present disclosure, assume that an icon corresponding to a first customer among one or more customers included in the first UI of Fig. 6a is selected. At this time, as illustrated in Fig. 6b, the device may display a third UI (630) that enables the purchase of multiple medicines sold by the first customer.

That is, the user can be provided with a third UI that allows the user to check each of the multiple pharmaceutical products sold by the first trading partner and purchase them.

Additionally or alternatively, the main screen displayed by the device may include a search UI (640) capable of searching for at least one of a business partner, a medicine, and an efficacy.

For example, based on a second business partner being searched for among at least one business partner through the search UI, the device may provide information on multiple pharmaceutical products sold by the second business partner through the search result UI.

As another example, based on a third-party drug being searched for through the search UI, the device may provide information about the third-party drug and information about multiple drugs of the same type as the third-party drug through the search results UI.

As another example, based on a specific efficacy being searched for through the search UI, the device may provide information on multiple pharmaceuticals targeting the specific efficacy through the search results UI.

Furthermore, the device may provide reliability for each of multiple pharmaceuticals targeting a specific efficacy through a search UI based on big data processing, based on the search for a specific efficacy. In this case, the higher the reliability rating, the more likely it is that the pharmaceutical exhibits a specific efficacy.

To this end, the device can access an external website (for example, a search engine website such as Google or Naver) to collect the number of keyword searches for a pharmaceutical targeting a specific efficacy for a specific period of time, access an external website (for example, a KIPRIS search engine website provided by the Patent Information Center) to collect whether a composition of a pharmaceutical targeting a specific efficacy has been patented for a specific period of time, and access an external website (for example, a search engine website such as Google or Naver) to collect the prices of pharmaceuticals from multiple sales sites sold through specific open markets for a specific efficacy. The device can estimate the reliability of the efficacy of the pharmaceutical based on the number of keyword searches described above, whether a patent has been registered, and the price of the pharmaceutical.

For example, if the absolute value of the difference between the maximum and average prices of the drug and the absolute value of the difference between the minimum and average prices are both greater than or equal to the first specific value, the device can set the reliability of the drug to the first level regardless of whether the patent is registered or the number of keyword searches. In other words, if the drug is sold at various price ranges from high to low on the web, it can be thought that the efficacy of the drug is not complete or that the quality is problematic and that the drug is distributed and sold through various routes.

In addition, the device may set the reliability to the second level regardless of the number of keyword searches if the absolute value of the difference between the maximum value and the average value of the price of the drug is equal to or greater than the first specific value and the absolute value of the difference between the minimum value and the average value is less than the first specific value, if the composition of the drug is patented, and may set the reliability to the second level if the number of keyword searches is less than the second specific value if the composition of the drug is not patented, and may set the reliability to the third level if the number of keyword searches is equal to or greater than the second specific value. That is, if there is a trend of the pharmaceutical being sold at a high price on the web, if the pharmaceutical is patented, it is judged that the market is filled with patented products (high price) and generic products (average price), and quality consistency is not guaranteed, so a relatively low trust rating is given. If it is not patented and cannot be monopolized by a specific person, the number of keyword searches is judged, and in the case of unpopular items with few keyword searches, if there is a trend of being sold at a high price, there is a high possibility that the efficacy of the pharmaceutical is not complete or there are quality issues, so a relatively low trust rating is given. In the case of popular items with many keyword searches, it can be judged that the route to a high price was created due to a distribution monopoly based on popularity regardless of the efficacy or quality of the pharmaceutical, so an intermediate trust rating is given.

In addition, the device can set the reliability to the second level regardless of whether the composition of the corresponding drug is patented or the number of keyword searches if the absolute value of the difference between the maximum and average prices of the drug is less than the first specific value and the absolute value of the difference between the minimum and average prices is greater than the first specific value. In other words, if the corresponding drug is sometimes sold at a low price on the web, there is a high possibility that the efficacy of the drug is not complete or there is a problem with the quality, so a relatively low reliability level is given.

Furthermore, if the absolute value of the difference between the maximum and average prices of the drug is less than the first specific value and the absolute value of the difference between the minimum and average prices is less than the first specific value, if the composition of the drug is not patented and the number of keyword searches is less than the second specific value, the reliability can be set to the fourth level, if the number of keyword searches is greater than or equal to the second specific value, the reliability can be set to the fifth level, and if the composition of the drug is patented, the reliability can be set to the sixth level regardless of the number of keyword searches. In other words, the drug is sold at a stabilized price range on the web, which means that its efficacy and quality have been recognized, and if it has been patented, it can be seen that the patentee has dominated the market, so it is given a higher level of reliability because it indicates more stable efficacy and quality, and if not, it is given a reliability level that is one level lower depending on its fame.

Here, the priority of each of at least one medicine provided in the search result UI can be determined based on the evaluation score and price of each of at least one medicine. Specifically, each of at least one medicine can have evaluation scores entered by multiple users mapped to it.

The device can apply a first weight to the evaluation score mapped to each of at least one pharmaceutical product, and can apply a second weight to the price of each of at least one pharmaceutical product. The device can obtain a first intermediate value by multiplying the evaluation score mapped to each of at least one pharmaceutical product by the first weight, and can obtain a second intermediate value by multiplying the price of each of at least one pharmaceutical product by the second weight (e.g., the second weight is a negative number). The device can obtain a value representing the priority of each of at least one pharmaceutical product by adding the first intermediate value and the second intermediate value for each of at least one pharmaceutical product.

The device can arrange at least one medicine in the search result UI according to the priority of each of the at least one medicine determined (i.e., according to a numerical value representing the priority of each of the at least one medicine). For example, a medicine with a higher priority can be arranged preferentially in the search result UI.

The size of each of the first weight and the second weight can be selected/determined by the device. That is, the size of the first weight and the second weight can be determined based on which item the user considers important, either price or evaluation score.

Based on the selection of the first medicine among multiple medicines through the third UI, the device can display a fourth UI that can order the first medicine and a fifth UI that includes information on multiple medicines of the same type as the first medicine sold by other business partners except the first business partner (S330).

As an example of the present disclosure, it is assumed that an icon corresponding to the first medicine is selected through the third UI (630) of Fig. 6b. At this time, as illustrated in Fig. 6c, the device can display on the main screen a fourth UI (650) that can order the first medicine and a fifth UI (660) that includes information on a plurality of medicines of the same type as the first medicine sold by other business partners except for the first business partner.

At this time, the fourth UI (650) may include the efficacy, effect, usage, and dosage of the first medicine. In addition, the fourth UI (650) may download a brochure for the first medicine. As another example, the fourth UI (650) may include a separate UI that can load and display a brochure for the first medicine.

Accordingly, users can more efficiently understand the efficacy, effectiveness, usage, and dosage of the first medicine sold by the first trading partner. In addition, users can easily download the brochure of the medicine they wish to purchase through the 4th UI without having to search for it separately.

Additionally or alternatively, assume that a second drug among multiple drugs of the same type as the first drug is selected through the fifth UI (660). In this case, the device can provide comparison information between the first drug and the second drug.

For example, comparison information between the first drug and the second drug may include price comparison information, efficacy comparison information, evaluation score comparison information, and discount information according to order quantity between the first drug and the second drug.

Specifically, the device can load the price, efficacy, evaluation score, and discount information based on the order quantity of the second drug. The device can provide a separate comparison UI that can compare the price, efficacy, evaluation score, and discount information based on the order quantity of each of the first drug and the second drug.

Comparison information between the first drug and the second drug may be provided as a separate UI overlaid on the fifth UI (660) or may be provided on the fifth UI.

Based on a user command being entered to order a first quantity of the first medicine through the fourth UI, the device can update the second UI based on information related to the purchase of the first quantity of the first medicine (S340).

As an example of the present disclosure, as illustrated in FIG. 6c, when a first quantity of the first medicine is ordered through the fourth UI (650), the device can add information indicating that the first quantity of the first medicine has been ordered from the first business partner to the second UI (620).

Additionally, the second UI may include an icon for canceling or refunding all or part of the first quantity of the first medicine purchased by the user. For example, if payment for the first quantity of the first medicine has been completed, the second UI may include an icon for refunding all or part of the first quantity of the first medicine purchased by the user.

Based on the selection of the icon for refunding all or part of the first medicine, the device may provide an inquiry UI for inquiring about the reason for refunding all or part of the first medicine. The device may transmit the reason for refunding all or part of the first medicine entered in the inquiry UI to the terminal device used by the first transaction party.

Accordingly, the first business partner can easily analyze the user's reasons for refund and establish sales strategies, etc. by supplementing the analysis.

Additionally, if the user has completed payment for the first quantity of the first medicine, the device may transmit the user's order information for the first quantity of the first medicine to the terminal device used by the first business partner. The device may receive the delivery schedule information of the first medicine received from the terminal device used by the first business partner and the delivery company used by the first business partner. The device may provide the delivery schedule information of the first medicine to the user.

For example, as illustrated in FIG. 6d, the device may provide a payment UI (670) that indicates the user's order history, delivery status, and payment status.

FIG. 4 is a flowchart illustrating a method for negotiating a pharmaceutical purchase via a video conference according to one embodiment of the present disclosure.

The device may provide a first message asking the user whether to request a consultation with the first vendor for additional purchase of the first medicine (S410).

Specifically, if the user has purchased the first medicine, the device may inquire whether to purchase additional first medicine after a predefined time. At this time, the device may provide a first message inquiring the user whether to request a consultation with the first vendor for additional purchase of the first medicine.

That is, if the user intends to purchase the first drug on a regular basis, the device may provide a first message to inquire whether the user would like to communicate directly with the first vendor to purchase the drug on better terms.

In response to the first message, based on the user requesting a consultation with the first business partner, the device can transmit a second message requesting a consultation for additional purchase of the user's first medicine to the terminal device used by the first business partner (S420).

For example, the device may transmit the second message to an account corresponding to the first transaction party (i.e., an account of the first transaction party registered with the application and/or website) through an application and/or website operating an electronic transaction ledger management service. For example, the device may transmit the second message to an account of a person in charge of the first pharmaceutical among the accounts corresponding to the first transaction party and/or an account of a person in charge covering the area where the user is located.

The second message may include a UI that allows the user to coordinate schedules between the user and the first business partner. When the second message inputs a schedule for the first business partner to meet, the device may transmit the input schedule to the user's account via an application and/or website that operates an electronic ledger management service.

Based on the coordination of schedules between the user and the first business partner, the device can provide a video meeting UI that can conduct a video meeting with the terminal device used by the first business partner according to the coordinated schedule (S430).

That is, the device may provide a video meeting UI through which the user and the first business partner may conduct a video meeting via an application and/or website that operates an electronic transaction ledger management service. Through the video meeting UI, the user and the first business partner may discuss additional purchase conditions of the first pharmaceutical product.

The device can purchase additional medicines through the purchase UI included in the video meeting UI (S440).

Specifically, if the terms of purchase of the first medicine or other medicine are agreed upon between the user and the first business partner, the device can generate an electronic contract based on the terms of purchase of the first medicine or other medicine. That is, the device can provide a UI that can conclude an electronic contract based on the terms of purchase agreed upon between the user and the first business partner while conducting a video meeting UI.

Additionally or alternatively, the device may generate an electronic contract based on the agreed upon terms via the video meeting UI or a separate communication tool (e.g., email, etc.) after the video meeting UI has ended.

When an electronic contract is concluded between the user and the first business partner, the device may provide a purchase UI included in the video meeting UI. That is, the video meeting UI may include a purchase UI that enables the purchase of multiple medicines sold by the first business partner.

Additionally or alternatively, a QR (quick response) code and/or a URL (uniform resource locator) address may be included in the electronic contract to access a purchase UI for purchasing multiple pharmaceutical products sold by the first business partner. After the video meeting ends, the device may access the purchase UI for purchasing multiple pharmaceutical products sold by the first business partner through the QR code and/or the URL address. The purchase UI may include UI elements for purchasing multiple pharmaceutical products based on the terms agreed upon in the electronic contract.

That is, the user can purchase the first medicine or other medicines through the purchase UI according to the purchase conditions agreed upon by the electronic contract. For example, the price of the fourth medicine purchased through the purchase UI among the multiple medicines sold by the first business partner can be determined by agreement between the first business partner and the user.

FIG. 5 is a flowchart illustrating a method for performing payment and return procedures for pharmaceutical products according to one embodiment of the present disclosure.

The device can display a main screen including a first icon for selecting a return UI and a second icon for selecting a payment UI related to payment of a first plurality of pharmaceutical orders (S510).

Specifically, the main screen may display a main screen including a first icon for selecting a return UI related to returning some or all of the first plurality of pharmaceutical products ordered from one or more business partners, and a second icon for selecting a payment UI related to payment of the first plurality of pharmaceutical products order.

For example, the first icon and the second icon can be implemented in the form of a banner that can change the mode of the main screen.

Based on the selection of the second icon, the device can display a selection UI for selecting a payment method for each order of the first plurality of medicines and a payment UI including first information indicating a payment status for each order of the first plurality of medicines (S520).

As an example of the present disclosure, as illustrated in FIG. 6e, the device can set the payment method for each of the first plurality of medicines ordered by the user as an automatic payment method or a manual payment method through the selection UI (680). Here, the automatic payment method means a method of automatically paying the medicine price on a specific date using a specific card, deposit, etc.

Based on the second information being entered to set the payment method of at least one of the first plurality of medicines to automatic payment through the selection UI, the device can perform a payment procedure for the at least one first medicine based on the second information (S530).

For example, the second information may include payment method, whether to pay in installments, payment date, type of card to be used for payment, etc.

For example, the payment UI may include a UI element that allows selection of one of one or more business partners. Based on the selection of a first business partner from the one or more business partners through the UI element, the payment UI may be updated to allow selection of a payment method for a drug ordered from the first business partner from among the plurality of drugs.

This allows users to select a payment method only for medicines ordered from specific vendors among the medicines they ordered.

As an example of the present disclosure, the device may collect types of a second plurality of medicines for which a payment procedure has been performed via a payment UI within a predefined time period and types of business partners corresponding to each type of the second plurality of medicines. In this case, the predefined time period (e.g., one month, etc.) may be determined by the user.

Based on the payment quantity of a specific type of medicine corresponding to the second customer among the types of the second plurality of medicines exceeding a threshold during a predefined time period, the device can transmit a recommendation message related to the sale of the specific type of medicine to a terminal device used by the second customer.

Specifically, a payment quantity of a specific type of medicine corresponding to a second vendor among the types of the second plurality of medicines exceeding a threshold value during a predefined time period may mean that the user regularly purchases a specific type of medicine sold by the second vendor.

The device may transmit a recommendation message related to the sale of a specific type of pharmaceutical product to a terminal device used by the second party so that the second party can manage the user as a regular customer.

For example, the device may transmit a recommendation message to a terminal device used by a second party recommending that the device transmit discount information for a particular type of medicine to the user.

As another example, the device may transmit a recommendation message to a terminal device used by a second party suggesting that the user conduct a meeting related to the sale of a particular type of pharmaceutical product.

When a message is received from a second party requesting a meeting with the user regarding the sale of a specific type of pharmaceutical product, the device may provide a message to the user asking whether to conduct a video meeting UI with the second party. If the user agrees to the message, the device may provide a video UI that allows the user and the second party to conduct a video meeting.

As an example of the present disclosure, the return UI may include third information about at least one second medicine that can be returned among the at least one first medicine. As an example, the at least one second medicine may include a medicine that has not yet been delivered and/or a medicine that is damaged, etc. among the at least one first medicine ordered and paid for by the user.

Based on the fact that at least one of the second pharmaceuticals is returned with at least one return reason through the return UI, the server and/or the device may record the return reason for each of at least one vendor selling each of the second at least one pharmaceuticals. That is, the server and/or the device may classify and collect the return reason for each vendor selling the returned pharmaceuticals.

Based on a threshold number of times a specific return reason is collected for at least one third party among the business partners, the server and/or the device can transmit a consulting message related to the specific return reason to a terminal device used by the third party.

For example, if a specific reason for return is related to a scratch or damage on the pharmaceutical product, the device may transmit a consulting message to the terminal device used by the third-party vendor, including a message suggesting that the vendor that delivers the pharmaceutical product be changed and/or a message suggesting that the method of storing the pharmaceutical product be checked.

Here, the message suggesting to change the vendor that delivers the pharmaceutical to the third party vendor may include information recommending the vendor. The server and/or device may identify the location of the warehouse of the third party vendor that releases the pharmaceutical to deliver the pharmaceutical to the user. The device may identify a plurality of vendors located within a certain distance range from the location of the identified warehouse.

The server and/or device may transmit a consulting message containing information about one or more shipping companies, excluding the shipping company currently used, among multiple shipping companies, to a terminal device used by a third-party business partner.

As another example, if a specific reason for return is related to the price of a pharmaceutical product, the server and/or device may transmit a message suggesting a discount event for the pharmaceutical product and/or a consulting message containing information on reducing costs associated with selling the pharmaceutical product to a terminal device used by the third-party business partner.

Information to reduce the cost of selling pharmaceuticals may be created by the person running the server, but may also be received from a terminal device used by a separate expert.

As another example, the server and/or device may input information required for a third-party vendor to sell a pharmaceutical product into a pre-trained artificial intelligence model (e.g., a generative artificial intelligence model) to obtain information for reducing the cost of selling the pharmaceutical product.

As an example of the present disclosure, the main screen may include a first UI for selecting multiple business partners and a third icon corresponding to a second UI indicating the user's transaction status.

Based on the selection of the first vendor in the first UI displayed when the third icon is selected by the user, the device may display a third UI for purchasing a third plurality of pharmaceutical products sold by the first vendor. The third UI may be configured based on information related to the third plurality of pharmaceutical products extracted from a pharmaceutical sales site operated by the first vendor.

For example, based on the selection of the first medicine from among the third plurality of medicines displayed on the third UI, a detailed UI including information about the first medicine may be displayed. Here, the detailed UI may include a first area indicating the efficacy and effect of the first medicine, a second area indicating the usage and dosage of the first medicine, a third area including an icon for downloading a brochure of the first medicine, and a fourth area for purchasing the first medicine.

In addition, information related to the third plurality of pharmaceutical products may include the types of the third plurality of pharmaceutical products sold in the sales mall operated by the first trading partner, and information on the efficacy, price, usage, and product brochures for each type of the third plurality of pharmaceutical products.

Specifically, each of the multiple business partners may operate a separate sales site for selling pharmaceuticals online. The third UI may be configured based on information for configuring the sales site operated separately by each of the multiple business partners.

For example, information for configuring a sales site operated separately by each of the multiple business partners may include the efficacy, effect, usage, dosage, evaluation score, brochure, etc. of the medicine sold by each of the multiple business partners. The terminal device used by each of the multiple business partners may transmit information for configuring the sales site to the server. Additionally or alternatively, the server may extract information for configuring the sales site from the sales site operated separately by each of the multiple business partners.

The server can configure a third UI for each of the multiple business partners and a detailed UI displayed when a specific medicine is selected in the third UI based on the information extracted directly and information received from terminal devices used by each of the multiple business partners.

For example, the server may configure a detailed UI corresponding to a specific medicine to include a first area indicating the efficacy and effect of the specific medicine, a second area indicating the usage and dosage of the specific medicine, a third area including an icon for downloading a brochure of the specific medicine, and a fourth area for purchasing the specific medicine.

Additionally, the server can also extract evaluation scores mapped to the medicines sold by each of the multiple vendors. The server can upload the evaluation scores and review data of a specific medicine on the detailed UI corresponding to the specific medicine.

Additionally, the server may receive advertising information (e.g., advertising banner, advertising image, advertising video) for at least one pharmaceutical from terminal devices used by each of the plurality of business partners. For example, the server may receive an advertising image for the first pharmaceutical from a terminal device used by the first business partner. The server may calculate an advertising cost corresponding to the size of the advertising image and the area to which the advertising image is attached. The server may create an electronic contract for the sale of the first pharmaceutical using the calculated advertising cost, etc. The server may attach the advertising image for the first pharmaceutical to a screen on an application and/or website that operates an electronic pharmaceutical transaction ledger management service according to the electronic contract.

Accordingly, the sales sites operated by each business partner can be linked and merged with the application that operates the electronic transaction ledger management service.

As another example of the present disclosure, the device and/or server may build a user's payment history in the form of a blockchain.

For example, based on a first quantity of a first medicine being paid for by a user, the device and/or server may generate a first block based on a hash value corresponding to payment information for the first quantity of the first medicine.

Based on the user returning some of the first quantity of the first medicine or purchasing additional amounts of the second quantity of the first medicine, the device and/or server may generate a second block based on a hash value corresponding to the history of returning some of the first quantity of the first medicine or purchasing additional amounts of the second quantity of the first medicine.

The device and/or server can build the user's payment history in the form of a blockchain by linking a second block to a first block.

Additionally or alternatively, the device and/or server may provide a UI that allows access to a virtual space containing virtual models corresponding to multiple business partners. The user may enter each of the virtual models corresponding to multiple business partners through an avatar corresponding to the user. Each of the virtual models corresponding to multiple business partners may have a representative avatar that can be consulted about the medicine being sold. The user may proceed with consultation about the medicine from the representative avatar.

As another example of the present disclosure, the device and/or server may collect patent-related information of a specific pharmaceutical product and assign a patent-related evaluation score to the specific pharmaceutical product.

For example, the server may receive patent information (e.g., application date, registration date, expiration date, information related to application for extension of duration, trial request information, litigation information, overseas patent family information) for at least one pharmaceutical from terminal devices used by each of a plurality of business partners. For example, the server may receive patent information for a first pharmaceutical from a terminal device used by a first business partner. The server may assign patent-related evaluation information for a specific pharmaceutical based on the patent information. In order to assign the patent-related evaluation information to the specific pharmaceutical, the server may receive patent-related information from a specific user, may receive patent-related evaluation information, and may upload patent-related evaluation evaluation information data for the specific pharmaceutical on a detailed UI corresponding to the specific pharmaceutical.

Patent-related evaluation information data for a specific pharmaceutical product may be provided and/or received from multiple business partners, or may be prepared by the person in charge of operating the server, but may also be received from a terminal device used by a separate expert.

Meanwhile, the disclosed embodiments may be implemented in the form of a recording medium storing instructions executable by a computer. The instructions may be stored in the form of program codes, and when executed by a processor, may generate program modules to perform the operations of the disclosed embodiments. The recording medium may be implemented as a computer-readable recording medium.

Computer-readable storage media include all types of storage media that store instructions that can be deciphered by a computer. Examples include ROM (Read Only Memory), RAM (Random Access Memory), magnetic tape, magnetic disk, flash memory, and optical data storage devices.

As described above, the disclosed embodiments have been described with reference to the attached drawings. Those skilled in the art to which the present disclosure pertains will understand that the present disclosure can be implemented in forms other than the disclosed embodiments without changing the technical idea or essential features of the present disclosure. The disclosed embodiments are exemplary and should not be construed as limiting.

100: Device
110: Memory
120: Communication Module
130: Display
140: Processor

Claims (5)

A method for providing a pharmaceutical electronic transaction ledger management service performed by a device, the method comprising:
A step of displaying a main screen including a first user interface (UI) for selecting one or more business partners and a second UI showing the user's transaction status;
A step of displaying a third UI for purchasing multiple pharmaceutical products sold by the first customer based on the selection of the first customer among the one or more customers through the first UI;
A step of displaying a fourth UI for ordering the first medicine and a fifth UI including information on a plurality of medicines of the same type as the first medicine sold by other business partners excluding the first business partner, based on the selection of the first medicine from among the plurality of medicines through the third UI;
A step of providing comparison information between the first drug and the second drug based on the selection of the second drug among multiple drugs of the same type as the first drug through the fifth UI; and
A step of updating the second UI based on information related to the purchase of the first quantity of the first medicine, based on a user command being input to order the first quantity of the first medicine through the fourth UI,
The second UI includes an icon for refunding all or part of the first quantity of the first medicine purchased;
Based on the selection of the above icon, an inquiry UI is provided asking why all or part of the first medicine is to be refunded.
The reason for refunding all or part of the first medicine entered in the above inquiry UI is transmitted to the terminal device used by the first business partner,
The above 4th UI includes the efficacy, effect, usage and dosage of the first drug,
Comparison information between the first medicine and the second medicine includes price comparison information, efficacy comparison information, evaluation score comparison information, and discount information according to order quantity between the first medicine and the second medicine.
The above main screen includes a search UI that allows you to search for effects,
Based on the search for a specific efficacy through the above search UI, information on multiple medicines targeting the specific efficacy is provided through the above search results UI.
Based on the search for a specific efficacy through the above search UI, the reliability of each of multiple pharmaceutical products targeting the specific efficacy is provided through the search results UI.
The device accesses an external website and collects the number of keyword searches for a plurality of pharmaceuticals targeting the specific efficacy for a specific period of time, collects whether the composition of the plurality of pharmaceuticals targeting the specific efficacy has been patented for a specific period of time, and collects the prices of the plurality of pharmaceuticals targeting the specific efficacy from a plurality of sales sites.
The above device sets the reliability of the drug to the first level regardless of whether a patent is registered or the number of keyword searches, if the absolute value of the difference between the maximum and average prices of multiple drugs targeting the specific efficacy and the absolute value of the difference between the minimum and average prices are both equal to or greater than the first specific value.
The above device sets the reliability to a second grade higher than the first grade regardless of the number of keyword searches when the composition of the plurality of pharmaceuticals targeting the specific efficacy is patented if the absolute value of the difference between the maximum value and the average value of the prices of the plurality of pharmaceuticals targeting the specific efficacy is equal to or greater than the first specific value and the absolute value of the difference between the minimum value and the average value is less than the first specific value, and sets the reliability to a third grade higher than the second grade when the number of keyword searches is less than the second specific value when the composition of the plurality of pharmaceuticals targeting the specific efficacy is not patented.
The above device sets the reliability to the second level, regardless of whether the composition of the multiple pharmaceuticals targeting the specific efficacy is patented or the number of keyword searches, when the absolute value of the difference between the maximum and average prices of the multiple pharmaceuticals targeting the specific efficacy is less than the first specific value and the absolute value of the difference between the minimum and average prices is greater than the first specific value.
The above device is a method wherein, if the absolute value of the difference between the maximum value and the average value of the prices of a plurality of pharmaceuticals targeting the specific efficacy is less than a first specific value and the absolute value of the difference between the minimum value and the average value is less than the first specific value, if the composition of the plurality of pharmaceuticals targeting the specific efficacy is not patented and the number of keyword searches is less than the second specific value, the reliability is set to a fourth grade higher than the third grade, if the number of keyword searches is equal to or greater than the second specific value, the reliability is set to a fifth grade higher than the fourth grade, and if the composition of the plurality of pharmaceuticals targeting the specific efficacy is patented, the reliability is set to a sixth grade higher than the fifth grade regardless of the number of keyword searches. delete delete delete delete